Filtered By:
Therapy: Transfusion Therapy

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 308 results found since Jan 2013.

Chronic transfusion therapy for stroke in sickle cell disease
Source: Journal of Clinical Apheresis - February 5, 2017 Category: Hematology Authors: Michael R. DeBaun, Keith Quirolo Tags: LETTER TO THE EDITOR Source Type: research

Primary stroke prevention in children with sickle cell anemia living in africa: the false choice between patient-oriented research and humanitarian service.
PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE. Trans Am Clin Climatol Assoc. 2016;127:17-33 Authors: Debaun MR, Galadanci NA, Kassim AA, Jordan LC, Phillips S, Aliyu MH Abstract In the United States, primary stroke prevention in children with sickle cell anemia (SCA) is now the standard of care and includes annual transcranial Doppler ultrasound evaluation to detect elevated intracranial velocities; and for those at risk, monthly blood transfusion therapy for at least a year followed by the opt...
Source: Transactions of the American Clinical and Climatological Association - January 12, 2017 Category: Journals (General) Tags: Trans Am Clin Climatol Assoc Source Type: research

Pediatric Sickle Cell Disease - Past Successes and Future Challenges.
Abstract Once a fatal disease of childhood, more than 95% of patients born today with sickle cell disease (SCD) in developed countries are expected to survive into adulthood, largely because of improvements in supportive and preventive care (newborn screening, penicillin prophylaxis, transcranial Doppler (TCD) screening). Hydroxyurea (HU) therapy, the only oral medication currently available to prevent SCD complications, has become more widespread over the past 20 years. The NHLBI recommends that HU be offered to all patients with HbSS beginning at nine months of age, and the recently published Abnormal TCD with T...
Source: Pediatric Research - October 4, 2016 Category: Pediatrics Authors: Meier ER, Rampersad A Tags: Pediatr Res Source Type: research

Blood transfusion services for patients with sickle cell disease in Nigeria
Conclusion Current efforts of Nigerian public hospitals to provide safe blood and CTT fall short of best practice. Provision of apheresis machines, improvement of voluntary non-remunerated donor drive, screening for red cell antigens and antibodies, and availability of iron chelators would significantly improve SCD care in Nigeria.
Source: International Health - September 27, 2016 Category: Global & Universal Authors: Diaku-Akinwumi, I. N., Abubakar, S. B., Adegoke, S. A., Adeleke, S., Adewoye, O., Adeyemo, T., Akinbami, A., Akinola, N. O., Akinsulie, A., Akinyoola, A., Aneke, J., Awwalu, S., Babadoko, A., Brown, B., Ejike, O., Emodi, I., George, I., Girei, A., Hassan, Tags: Original Article Source Type: research

Management of Patients with Sickle Cell Disease Using Transfusion Therapy
Publication date: June 2016 Source:Hematology/Oncology Clinics of North America, Volume 30, Issue 3 Author(s): Stella T. Chou, Ross M. FasanoTeaser Red blood cell (RBC) transfusion therapy is a key component of comprehensive management of patients with sickle cell disease (SCD) and has increased over time as a means of primary and secondary stroke prevention. RBC transfusions also prove to be lifesaving for many acute sickle cell–related complications. Although episodic and chronic transfusion therapy has significantly improved the morbidity and mortality of patients with SCD, transfusions are not without adverse eff...
Source: Hematology Oncology Clinics of North America - April 23, 2016 Category: Hematology Source Type: research

Reduction in Overt and Silent Stroke Recurrence Rate Following Cerebral Revascularization Surgery in Children with Sickle Cell Disease and Severe Cerebral Vasculopathy
ConclusionsThe rate of overt and silent infarct recurrence was significantly lower following indirect cerebral revascularization. A prospective study of cerebral revascularization in children with SCD is needed.
Source: Pediatric Blood and Cancer - April 21, 2016 Category: Cancer & Oncology Authors: Erin M. Hall, Jeffrey Leonard, Jodi L. Smith, Kristin P. Guilliams, Michael Binkley, Robert J. Fallon, Monica L. Hulbert Tags: Research Article Source Type: research

Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients.
CONCLUSION: We recommend RCE plus chelation as an effective method for reducing iron overload, while maintaining HbS at 30% to 35%. PMID: 26997031 [PubMed - as supplied by publisher]
Source: Transfusion - March 19, 2016 Category: Hematology Authors: Fasano RM, Leong T, Kaushal M, Sagiv E, Luban NL, Meier ER Tags: Transfusion Source Type: research

Central nervous system complications and management in sickle cell disease
With advances in brain imaging and completion of randomized clinical trials (RCTs) for primary and secondary stroke prevention, the natural history of central nervous system (CNS) complications in sickle cell disease (SCD) is evolving. In order of current prevalence, the primary CNS complications include silent cerebral infarcts (39% by 18 years), headache (both acute and chronic: 36% in children with sickle cell anemia [SCA]), ischemic stroke (as low as 1% in children with SCA with effective screening and prophylaxis, but ~11% in children with SCA without screening), and hemorrhagic stroke in children and adults with SCA ...
Source: Blood - February 18, 2016 Category: Hematology Authors: DeBaun, M. R., Kirkham, F. J. Tags: Sickle Cell Disease, Free Research Articles, Red Cells, Iron, and Erythropoiesis, Review Articles, Review Series, Clinical Trials and Observations Source Type: research

Transfusion therapy for sickle cell disease
The clinical presentations of sickle cell disease include acute pain, acute chest syndrome, stroke and acute anaemia and blood transfusion therapy can be used effectively in the emergency setting for the treatment of many of these complications. Long‐term blood transfusion therapy is also used for the prevention of disease complications with most evidence for its use in primary stroke prevention. Transfusion can be given as a simple or top‐up transfusion or as an exchange transfusion and donor red cells should be haemoglobin S negative and as a minimum matched for ABO, full Rh and Kell type. Repeated transfusions lead ...
Source: ISBT Science Series - January 29, 2016 Category: Hematology Authors: J. Howard, S. E. Robinson Tags: Invited Review Source Type: research

Management of Sickle Cell Disease: Recommendations from the 2014 Expert Panel Report.
Abstract Family physicians are the primary and sometimes only health care resource for families affected by sickle cell disease. Recently published guidelines provide important recommendations for health maintenance, acute care, and monitoring of disease-modifying therapy in persons with this condition. This overview highlights some of the most important clinical activities that can and should be carried out in the community care setting. Children with sickle cell anemia should receive prophylactic penicillin from birth through at least five years of age, and all persons with sickle cell disease require vaccinatio...
Source: American Family Physician - December 15, 2015 Category: Primary Care Authors: Yawn BP, John-Sowah J Tags: Am Fam Physician Source Type: research

Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial
We report the baseline findings of abdominal organ iron burden in 121 participants. At enrollment, patients were young (9·8 ± 2·9 years), predominantly female (60:40), and previously treated with transfusions (4·1 ± 2·4 years) and iron chelation (3·1 ± 2·1 years). Liver iron concentration (LIC; 9·0 ± 6·6 mg/g dry weight) and serum ferritin were moderately elevated (2696 ± 1678 μg/l), but transferrin was incompletely saturated (47·2 ± 23·6%). Spleen R2* was 509 ± 399 Hz (splenic iron ~13·9 mg/g) and correlated with LIC (r2 = 0·14, P = 0·0008). Pancreas R2* was increased in 38·3...
Source: British Journal of Haematology - November 2, 2015 Category: Hematology Authors: John C. Wood, Alan R. Cohen, Sara L. Pressel, Banu Aygun, Hamayun Imran, Lori Luchtman‐Jones, Alexis A. Thompson, Beng Fuh, William H. Schultz, Barry R. Davis, Russell E. Ware, Tags: Research Paper Source Type: research

Immunophenotypic Parameters and RBC Alloimmunization in Children with Sickle Cell Disease on Chronic Transfusion
This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - September 1, 2015 Category: Hematology Authors: Robert S. Nickel, John T. Horan, Ross M. Fasano, Erin Meyer, Cassandra D. Josephson, Anne M. Winkler, Marianne E. M. Yee, Leslie S. Kean, Jeanne E. Hendrickson Tags: Research Article Source Type: research

How I treat and manage strokes in sickle cell disease
Neurologic complications are a major cause of morbidity and mortality in sickle cell disease (SCD). In children with sickle cell anemia, routine use of transcranial Doppler screening, coupled with regular blood transfusion therapy, has decreased the prevalence of overt stroke from ~11% to 1%. Limited evidence is available to guide acute and chronic management of individuals with SCD and strokes. Current management strategies are based primarily on single arm clinical trials and observational studies, coupled with principles of neurology and hematology. Initial management of a focal neurologic deficit includes evaluation by...
Source: Blood - May 28, 2015 Category: Hematology Authors: Kassim, A. A., Galadanci, N. A., Pruthi, S., DeBaun, M. R. Tags: Sickle Cell Disease, How I Treat, Free Research Articles, Red Cells, Iron, and Erythropoiesis, Clinical Trials and Observations Source Type: research

Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis
We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death. We followed 43 children with sickle cell disease from 2000 to 2009 after having a first clinical stroke, of whom 10 opted for HU therapy. HU use led to decreased stroke recurrence and death without significantly increasing the annual cost of care per patient (J$83,250 vs. J$76,901, P = 0.491). The incremental cost effectiveness ratio (ICER) for prevention of stroke recurrence amounted to J$169,238 (US$1,900), while that for death prevention equalled J$635,843 (US$7,140). HU may be recommended when safe and...
Source: Pediatric Blood and Cancer - April 30, 2015 Category: Cancer & Oncology Authors: Colette Cunningham‐Myrie, Abdullahi Abdulkadri, Andre Waugh, Susanna Bortolusso Ali, Lesley‐Gaye King, Jennifer Knight‐Madden, Marvin Reid Tags: Brief Report Source Type: research